{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:07:20Z","timestamp":1791882440072,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bcp.2020.114356","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T11:12:59Z","timestamp":1607080379000},"page":"114356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Overcoming interferon (IFN)-\u03b3 resistance ameliorates transforming growth factor (TGF)-\u03b2-mediated lung fibroblast-to-myofibroblast transition and bleomycin-induced pulmonary fibrosis"],"prefix":"10.1016","volume":"183","author":[{"given":"Chun-Jung","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiou-Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Chi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chia","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Wen","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.bcp.2020.114356_b0005","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic Pulmonary Fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9779","key":"10.1016\/j.bcp.2020.114356_b0010","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"CAPACITY Study Group, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.bcp.2020.114356_b0015","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"INPULSIS Trial Investigators, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2020.114356_b0020","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2353\/ajpath.2007.070112","article-title":"The myofibroblast: one function, multiple origins","volume":"170","author":"Hinz","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2020.114356_b0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-pathol-012513-104706","article-title":"Pathogenesis of idiopathic pulmonary fibrosis","volume":"9","author":"Wolters","year":"2014","journal-title":"Annu. Rev. Pathol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114356_b0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1513\/pats.201203-023AW","article-title":"The impact of TGF-\u03b2 on lung fibrosis: from targeting to biomarkers","volume":"9","author":"Fernandez","year":"2012","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"1","key":"10.1016\/j.bcp.2020.114356_b0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1755-1536-5-11","article-title":"Molecular and cellular mechanisms of pulmonary fibrosis","volume":"5","author":"Todd","year":"2012","journal-title":"Fibrogen. Tissue Repair"},{"issue":"3","key":"10.1016\/j.bcp.2020.114356_b0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1165\/rcmb.2016-0121TR","article-title":"Immune Mechanisms in Pulmonary Fibrosis","volume":"55","author":"Kolahian","year":"2016","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114356_b0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","article-title":"TGF-\u03b2 activation and function in immunity","volume":"32","author":"Travis","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2020.114356_b0050","doi-asserted-by":"crossref","first-page":"L92","DOI":"10.1152\/ajplung.2001.281.1.L92","article-title":"IL-12 attenuates bleomycin-induced pulmonary fibrosis","volume":"281","author":"Keane","year":"2001","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.bcp.2020.114356_b0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000073718","article-title":"Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro","volume":"132","author":"Saito","year":"2003","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.bcp.2020.114356_b0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","article-title":"Fibrotic disease and the T(H)1\/T(H)2 paradigm","volume":"4","author":"Wynn","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2020.114356_b0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1378\/chest.123.1.209","article-title":"Interferons and their application in the diseases of the lung","volume":"123","author":"Antoniou","year":"2003","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.bcp.2020.114356_b0070","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3109\/01902149509050842","article-title":"Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression","volume":"21","author":"Gurujeyalakshmi","year":"1995","journal-title":"Exp. Lung Res."},{"issue":"6721","key":"10.1016\/j.bcp.2020.114356_b0075","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/17826","article-title":"Inhibition of transforming growth factor-beta\/SMAD signalling by the interferon-gamma\/STAT pathway","volume":"397","author":"Ulloa","year":"1999","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2020.114356_b0080","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1165\/ajrcmb.26.4.4784","article-title":"Interleukin-4- and interleukin-13-enhanced transforming growth factor-beta2 production in cultured human bronchial epithelial cells is attenuated by interferon-gamma","volume":"26","author":"Wen","year":"2002","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"issue":"9685","key":"10.1016\/j.bcp.2020.114356_b0085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","article-title":"INSPIRE Study Group, Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial","volume":"374","author":"Jr King","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2020.114356_b0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa030511","article-title":"Idiopathic Pulmonary Fibrosis Study Group, A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis","volume":"350","author":"Raghu","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2020.114356_b0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1164\/rccm.200312-1670OC","article-title":"Idiopathic Pulmonary Fibrosis Biomarkers Study Group, Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis","volume":"170","author":"Strieter","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.bcp.2020.114356_b0100","first-page":"37","article-title":"Inhaled Interferon and Diffusion Capacity in Idiopathic Pulmonary Fibrosis (IPF)","volume":"32","author":"Skaria","year":"2015","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"4","key":"10.1016\/j.bcp.2020.114356_b0105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.cr.7290055","article-title":"The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions","volume":"10","author":"Qu","year":"2000","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bcp.2020.114356_b0110","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1038\/s41467-018-05768-3","article-title":"The tyrosine phosphatase SHP2 controls TGF\u03b2-induced STAT3 signaling to regulate fibroblast activation and fibrosis","volume":"9","author":"Zehender","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2020.114356_b0115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12931-018-0728-9","article-title":"The JAK2 pathway is activated in idiopathic pulmonary fibrosis","volume":"19","author":"Milara","year":"2018","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.bcp.2020.114356_b0120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/thoraxjnl-2017-210728","article-title":"JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study","volume":"73","author":"Milara","year":"2018","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.bcp.2020.114356_b0125","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1164\/rccm.201602-0329OC","article-title":"SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis","volume":"195","author":"Tzouvelekis","year":"2017","journal-title":"Am. J. Respir. Crit. Care. Med."},{"issue":"3","key":"10.1016\/j.bcp.2020.114356_b0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0167-4889(02)00322-1","article-title":"Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response","volume":"1592","author":"Qu","year":"2002","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.bcp.2020.114356_b0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0065-230X(10)06002-1","article-title":"The tyrosine phosphatase Shp2 in development and cancer","volume":"106","author":"Grossmann","year":"2010","journal-title":"Adv. Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2020.114356_b0140","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejmg.2015.08.005","article-title":"SHP2 sails from physiology to pathology","volume":"58","author":"Tajan","year":"2015","journal-title":"Eur. J. Med. Genet."},{"issue":"6","key":"10.1016\/j.bcp.2020.114356_b0145","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1172\/JCI87037","article-title":"Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus","volume":"126","author":"Wang","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bcp.2020.114356_b0150","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1128\/MCB.19.3.2416","article-title":"Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak\/STAT pathway","volume":"19","author":"You","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcp.2020.114356_b0155","doi-asserted-by":"crossref","unstructured":"E. De Langhe, G. Vande Velde, J. Hostens, U. Himmelreich, B. Nemery, F.P. Luyten, J. Vanoirbeek, R.J. Lories, Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography, PLoS One 7 (8) (2012) e43123.","DOI":"10.1371\/journal.pone.0043123"},{"key":"10.1016\/j.bcp.2020.114356_b0160","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.phrs.2015.04.012","article-title":"Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions","volume":"97","author":"Della Latta","year":"2013","journal-title":"Pharmacol. Res."},{"issue":"43","key":"10.1016\/j.bcp.2020.114356_b0165","doi-asserted-by":"crossref","first-page":"41677","DOI":"10.1074\/jbc.M306461200","article-title":"Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors","volume":"278","author":"Araki","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114356_b0170","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1074\/jbc.M509595200","article-title":"The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling","volume":"281","author":"Wormald","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114356_b0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1755-1536-3-15","article-title":"Mesenchymal cell survival in airway and interstitial pulmonary fibrosis","volume":"3","author":"Bonner","year":"2010","journal-title":"Fibrogen. Tissue Repair"},{"issue":"1","key":"10.1016\/j.bcp.2020.114356_b0180","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1465-9921-14-102","article-title":"Role of IGF-1 pathway in lung fibroblast activation","volume":"14","author":"Hung","year":"2013","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.bcp.2020.114356_b0185","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0002-9440(10)62263-8","article-title":"Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition","volume":"166","author":"Pilewski","year":"2005","journal-title":"Am. J. Pathol."},{"issue":"42","key":"10.1016\/j.bcp.2020.114356_b0190","doi-asserted-by":"crossref","first-page":"16975","DOI":"10.1073\/pnas.1315862110","article-title":"STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor","volume":"110","author":"Wang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.bcp.2020.114356_b0195","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4049\/jimmunol.170.3.1383","article-title":"Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses","volume":"170","author":"Ding","year":"2003","journal-title":"J. Immunol."},{"issue":"52","key":"10.1016\/j.bcp.2020.114356_b0200","doi-asserted-by":"crossref","first-page":"35056","DOI":"10.1074\/jbc.273.52.35056","article-title":"The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities","volume":"273","author":"Song","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2020.114356_b0205","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ni1104","article-title":"PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity","volume":"5","author":"Liu","year":"2004","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.bcp.2020.114356_b0210","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.4049\/jimmunol.163.10.5686","article-title":"IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis","volume":"163","author":"Keane","year":"1999","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2020.114356_b0215","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1165\/rcmb.2004-0175OC","article-title":"Inhibition of pulmonary fibrosis by the chemokine IP-10\/CXCL10","volume":"31","author":"Tager","year":"2004","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2020.114356_b0220","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/thoraxjnl-2016-208710","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume","volume":"72","author":"Kolb","year":"2017","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.bcp.2020.114356_b0225","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"10082","key":"10.1016\/j.bcp.2020.114356_b0230","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2020.114356_b0235","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/path.4104","article-title":"The myofibroblast matrix: implications for tissue repair and fibrosis","volume":"229","author":"Klingberg","year":"2013","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114356_b0240","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/ijms20030593","article-title":"Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets","volume":"20","author":"Ballester","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2020.114356_b0245","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat. Commun."},{"issue":"49","key":"10.1016\/j.bcp.2020.114356_b0250","doi-asserted-by":"crossref","first-page":"34152","DOI":"10.1074\/jbc.M113.546077","article-title":"SHP2 positively regulates TGF\u03b21-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1","volume":"289","author":"Li","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2020.114356_b0255","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/ijms18020395","article-title":"Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells","volume":"18","author":"Sun","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2020.114356_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104595","article-title":"Targeting SHP2 as a promising strategy for cancer immunotherapy","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2020.114356_b0265","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12964-019-0451-2","article-title":"The multi-site docking protein Grb2-associated binder 1 (Gab1) enhances interleukin-6-induced MAPK-pathway activation in an SHP2-, Grb2-, and time-dependent manner","volume":"17","author":"Bongartz","year":"2019","journal-title":"Cell Commun. Signal."},{"issue":"12","key":"10.1016\/j.bcp.2020.114356_b0270","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.freeradbiomed.2009.03.026","article-title":"Oxidative stress induces lipid-raft-mediated activation of Src homology 2 domain-containing protein-tyrosine phosphatase 2 in astrocytes","volume":"46","author":"Park","year":"2009","journal-title":"Free Radic. Biol. Med."},{"issue":"12","key":"10.1016\/j.bcp.2020.114356_b0275","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3858\/emm.2011.43.12.075","article-title":"Caveolin-1 is involved in reactive oxygen species-induced SHP-2 activation in astrocytes","volume":"43","author":"Yun","year":"2011","journal-title":"Exp. Mol. Med."},{"issue":"9","key":"10.1016\/j.bcp.2020.114356_b0280","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.imbio.2012.01.001","article-title":"Regulation of SHP2 by PTEN\/AKT\/GSK-3\u03b2 signaling facilitates IFN-\u03b3 resistance in hyperproliferating gastric cancer","volume":"217","author":"Tseng","year":"2012","journal-title":"Immunobiology"},{"issue":"3","key":"10.1016\/j.bcp.2020.114356_b0285","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.bbrc.2015.09.085","article-title":"Loss of PTEN causes SHP2 activation, making lung cancer cells unresponsive to IFN-\u03b3","volume":"466","author":"Chen","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2020.114356_b0290","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/15216540410001668064","article-title":"Intracellular proteins and mechanisms involved in the control of gp130\/JAK\/STAT cytokine signaling","volume":"56","author":"Carbia-Nagashima","year":"2004","journal-title":"IUBMB Life."},{"key":"10.1016\/j.bcp.2020.114356_b0295","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.rmed.2017.05.017","article-title":"Current approaches to the management of idiopathic pulmonary fibrosis","volume":"129","author":"Raghu","year":"2017","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.bcp.2020.114356_b0300","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.bcp.2020.114356_b0305","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd.2017.170","article-title":"Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease","volume":"16","author":"Mora","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.bcp.2020.114356_b0310","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1465-9921-15-16","article-title":"Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis","volume":"15","author":"Inomata","year":"2014","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.bcp.2020.114356_b0315","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12931-019-1171-2","article-title":"Interferon-\u03b3 enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation","volume":"20","author":"Vu","year":"2019","journal-title":"Respir. Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522030592X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522030592X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:25:31Z","timestamp":1757769931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522030592X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":63,"alternative-id":["S000629522030592X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114356","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming interferon (IFN)-\u03b3 resistance ameliorates transforming growth factor (TGF)-\u03b2-mediated lung fibroblast-to-myofibroblast transition and bleomycin-induced pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114356"}}